Valneva (NASDAQ:VALN) Upgraded at Wall Street Zen

by · The Cerbat Gem

Wall Street Zen upgraded shares of Valneva (NASDAQ:VALN – Free Report) to a hold rating in a report issued on Saturday.

Several other research firms have also recently commented on VALN. Jefferies Financial Group set a $14.00 target price on shares of Valneva and gave the stock a “buy” rating in a research note on Monday, August 25th. HC Wainwright restated a “buy” rating and issued a $18.00 target price on shares of Valneva in a research note on Monday, August 25th. Three analysts have rated the stock with a Buy rating, According to data from MarketBeat, the company presently has a consensus rating of “Buy” and a consensus price target of $15.00.

Check Out Our Latest Analysis on VALN

Valneva Stock Down 1.5%

Shares of NASDAQ:VALN opened at $8.52 on Friday. The stock has a market cap of $732.12 million, a P/E ratio of -8.69 and a beta of 1.78. The firm has a fifty day moving average price of $8.09 and a 200 day moving average price of $7.08. The company has a debt-to-equity ratio of 0.66, a current ratio of 2.27 and a quick ratio of 1.77. Valneva has a 1-year low of $3.62 and a 1-year high of $12.25.

Valneva (NASDAQ:VALN – Get Free Report) last released its earnings results on Tuesday, August 12th. The company reported ($0.16) EPS for the quarter, topping the consensus estimate of ($0.27) by $0.11. Valneva had a negative net margin of 33.87% and a negative return on equity of 34.78%. The company had revenue of $54.84 million during the quarter, compared to analysts’ expectations of $46.28 million. Sell-side analysts predict that Valneva will post 0.13 EPS for the current year.

Hedge Funds Weigh In On Valneva

A number of large investors have recently made changes to their positions in VALN. Frazier Life Sciences Management L.P. purchased a new position in shares of Valneva in the 2nd quarter valued at about $8,240,000. GAMMA Investing LLC purchased a new position in Valneva during the 1st quarter valued at about $94,000. Finally, Marex Group plc purchased a new position in Valneva during the 2nd quarter valued at about $64,000. Hedge funds and other institutional investors own 11.39% of the company’s stock.

About Valneva

(Get Free Report)

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.

Featured Articles